Alembic Pharma Receives Four Observations From U.S. FDA For Panelav Facility
Tablets are arranged for a photograph at a pharmacy in Jakarta, Indonesia. Photographer: Dimas Ardian/Bloomberg

Alembic Pharma Receives Four Observations From U.S. FDA For Panelav Facility

Bookmark

Alembic Pharmaceuticals on Monday said that U.S. health regulator has conducted an inspection at it Panelav facility in Gujarat and issued Form 483 with four procedural observations.

"The U.S. Food and Drug Administration has conducted an inspection at Alembic Pharmaceuticals general oral solid formulation facility located at Panelav from 9-13 March, 2020," the drug firm said in a filing to the exchanges.

This was a scheduled inspection, and at the end of the inspection, the U.S. FDA issued a Form 483 with four procedural observations.

Also read: Unichem Lab Gets USFDA Nod For Pain Management Drug

None of the observations are related to data integrity or repetitive in nature.

"The company will provide comprehensive corrective action report to address each observation. The company is committed to maintaining highest quality standards that meet U.S. FDA standards," it said.

The U.S. health regulator issues observations by means of a FDA Form 483 notifying the company's management of objectionable conditions at the facility inspected.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.